York, PA 的 乳癌 臨床試驗
8 項針對 乳癌 的研究正在 York（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- WellSpan York Cancer Center, York
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
招募中3 期
- Cancer Care Associates Of York ( Site 0063), York
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
招募中3 期
- Cancer Care Associates of York, Inc., York
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
招募中3 期
- WellSpan Health-York Cancer Center, York
- WellSpan Health-York Hospital, York
E-Mindfulness Approaches for Living After Breast Cancer
招募中3 期
- WellSpan Health-York Cancer Center, York
- UPMC Memorial, York
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
招募中3 期
- WellSpan Health-York Cancer Center, York
- WellSpan Health-York Hospital, York
Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
招募中觀察性研究
- WellSpan Health - York Cancer Center, York
CtDNA Based MRD Testing for NAC Monitoring in TNBC
招募中觀察性研究
- Cancer Care Associates of York, York
其他城市的 乳癌 試驗
- New York City, NY136 項研究
- Houston, TX126 項研究
- Boston, MA112 項研究
- Nashville, TN81 項研究
- Los Angeles, CA73 項研究
- Edison, NJ68 項研究
- St. Louis, MO64 項研究
- Queens, NY64 項研究
- Durham, NC64 項研究
- Chicago, IL59 項研究
- Philadelphia, PA56 項研究
- Dallas, TX55 項研究
York 的其他研究
- 非小細胞肺癌15 項研究
- 癌症（所有類型）8 項研究
- 肺癌8 項研究
- 頭頸部鱗狀細胞癌7 項研究
- 卵巢癌6 項研究
- 前列腺癌5 項研究
- 冠狀動脈疾病5 項研究
- 食道癌4 項研究
- 三陰性乳癌4 項研究
- 大腸直腸癌4 項研究
- 子宮內膜癌4 項研究
- 結腸癌3 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。